Kamlesh Bisht - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

All papers authored by Kamlesh Bisht

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

2024 Alana L. Keller, Lauren T. Reiman

ORCID

, Olivia Perez de Acha

ORCID

, Sarah E. Parzych

ORCID

, Peter A. Forsberg, Peter S. Kim, Kamlesh Bisht

ORCID

, Hongfang Wang, Helgi van de Velde, Daniel W. Sherbenou

Supplementary Figure 1 from Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies

Upload

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Alana L. Keller, Lauren T. Reiman

ORCID

, Olivia Perez de Acha

ORCID

, Sarah E. Parzych

ORCID

, Peter A. Forsberg, Peter S. Kim, Kamlesh Bisht

ORCID

, Hongfang Wang, Helgi van de Velde, Daniel W. Sherbenou

Supplementary Table 1 from Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies

Upload

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Alana L. Keller, Lauren T. Reiman

ORCID

, Olivia Perez de Acha

ORCID

, Sarah E. Parzych

ORCID

, Peter A. Forsberg, Peter S. Kim, Kamlesh Bisht

ORCID

, Hongfang Wang, Helgi van de Velde, Daniel W. Sherbenou

Supplementary Figure 3 from Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies

Upload

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Alana L. Keller, Lauren T. Reiman

ORCID

, Olivia Perez de Acha

ORCID

, Sarah E. Parzych

ORCID

, Peter A. Forsberg, Peter S. Kim, Kamlesh Bisht

ORCID

, Hongfang Wang, Helgi van de Velde, Daniel W. Sherbenou

Supplementary Figure 4 from Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies

Upload

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Alana L. Keller, Lauren T. Reiman

ORCID

, Olivia Perez de Acha

ORCID

, Sarah E. Parzych

ORCID

, Peter A. Forsberg, Peter S. Kim, Kamlesh Bisht

ORCID

, Hongfang Wang, Helgi van de Velde, Daniel W. Sherbenou

Supplementary Figure 2 from Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies

Upload

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Alana L. Keller, Lauren T. Reiman

ORCID

, Olivia Perez de Acha

ORCID

, Sarah E. Parzych

ORCID

, Peter A. Forsberg, Peter S. Kim, Kamlesh Bisht

ORCID

, Hongfang Wang, Helgi van de Velde, Daniel W. Sherbenou

Supplementary Figure 5 from Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies

Upload

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Alana L. Keller, Lauren T. Reiman

ORCID

, Olivia Perez de Acha

ORCID

, Sarah E. Parzych

ORCID

, Peter A. Forsberg, Peter S. Kim, Kamlesh Bisht

ORCID

, Hongfang Wang, Helgi van de Velde, Daniel W. Sherbenou

Data from Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies

Upload

Missing publications? Search for publications with a matching author name.